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Abstract: Radical cystectomy remains the gold standard for treatment of muscle-
invasive bladder cancer. Robot-assisted radical cystectomy has technical advantages
over laparoscopic radical cystectomy and has emerged as an alternative to open radical
cystectomy. Despite the advancements in robotic surgery, experience with total
intracorporeal reconstruction of urinary diversion remains limited. Most surgeons have
carried out the hybrid approach of robot-assisted radical cystectomy and extracorporeal
reconstruction of urinary diversion, as intracorporeal reconstruction of urinary diversion
remains technically challenging. However, intracorporeal reconstruction of urinary
diversion might potentially proffer additional benefits, such as decreased fluid loss,
reduction in estimated blood loss and a quicker return of bowel function. The adoption
of intracorporeal ileal neobladder reconstruction has hitherto been limited to high-
volume academic institutions. In the present review, we compare the totally
intracorporeal robot-assisted radical cystectomy approach with open radical cystectomy
and robot-assisted radical cystectomy + extracorporeal reconstruction of urinary
diversion in muscle-invasive bladder cancer patients.
Key words: intracorporeal urinary diversion, muscle-invasive bladder cancer,
neoadjuvant chemotherapy, radical cystectomy, robot-assisted surgery.
Introduction
RC remains the gold standard of treatment for MIBC and for high-grade, recurrent non-mus-
cle-invasive tumors. ORC is associated with high morbidity, with historical rates of postopera-
tive complications between 30% and 60% in large pelvic oncology centers.1–3 Minimally
invasive surgical techniques have been widely used in a variety of surgical procedures.4 LRC
might proffer beneﬁts in terms of EBL, analgesic requirements and reduced scarring.5 How-
ever, LRC is not widely adopted, because it is a challenging procedure.6 Conversely, RARC
has technical advantages over LRC, such as magniﬁed 3-D vision with a surgeon-controlled
camera, mechanical wrists with seven degrees of motion, motion scaling and tremor reduc-
tion.7 Therefore, RARC has emerged as a better alternative to ORC because of its possible
reduction in EBL, blood transfusion rate and postoperative analgesia, and quicker recovery of
bowel function.8,9
Although robotic surgery has advanced, experience in total ICUD, including
intracorporeal ileal conduit or neobladder reconstruction, remains limited. Most surgeons
have carried out the hybrid approach of RARC and ECUD, as ICUD, especially ICNB,
remains technically challenging.10,11 However, ICUD might have potential beneﬁts,
including decreased ﬂuid loss, reduced EBL and a quicker return of bowel function.12
The adoption of ICNB has hitherto been limited to high-volume academic institutions,
and several surgical techniques for ICNB have been reported with promising functional
outcomes.4,13–18
In the present review, we compare the totally intracorporeal RARC approach with ORC
and RARC + ECUD in MIBC patients, focusing on perioperative morbidities and oncological
outcomes.
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Perioperative morbidities
Although RC surgical technique and perioperative care have
improved in recent years, ORC still has a perioperative
mortality ranging from 0% to 8% and a morbidity ranging
from 48% to 74%.1–3,19 The Canadian Urological Associa-
tion investigated the quality of surgical care for MIBC
patients who underwent RC in Quebec from 2000 to
2009.19 A total of 2778 RC procedures were carried out in
48 hospitals by 122 urologists.19 Of the patients treated,
30.6% had at least one postoperative complication and
12.6% had more than one complication.19 The overall mor-
tality rates at 30, 60 and 90 days were 2.8%, 5.3% and
7.5%, respectively.19 The 30-, 60- and 90-day mortality
rates in high-volume centers were signiﬁcantly less than
those of small hospitals.19 Therefore, minimally invasive
surgical approaches have been rapidly adopted for the treat-
ment of MIBC worldwide.10
RARC has emerged as an alternative to ORC due to its
possible reduction of perioperative morbidities, including
EBL, blood transfusion rate, postoperative analgesia and
quicker recovery of bowel function.8,12,20 Matsumoto et al.
reported a mean EBL of 1700 mL for the ORC group,
961 mL for the LRC group and 450 mL for the RARC
group (P = 0.004), and only the ORC group required blood
transfusion (P = 0.003).6 Gandaglia et al. reported the peri-
operative outcomes of RARC and ORC in patients with
BCa who were treated in two high-volume centers.21 The
median operative time was signiﬁcantly longer in patients
who underwent RARC than in those who underwent ORC
(330 vs 185 min, respectively; P < 0.001).21 Patients treated
by RARC had a shorter LOS (13 vs 20 days, respectively;
P < 0.001).21 The rates of overall and low-grade complica-
tions were also signiﬁcantly higher in the RARC patients
(all P ≤ 0.01).21 Li et al. carried out a systematic review
and meta-analysis of available literature comparing RARC
and ORC in BCa patients.22 Based on data pooled from
nine studies involving 668 MIBC patients, RARC had sig-
niﬁcantly longer operative time, lower EBL and shorter
LOS than ORC (all P < 0.001).22 Although there were no
signiﬁcant differences in intraoperative and postoperative
complication rates between the two groups, major
complications were signiﬁcantly lower in the RARC group
than in the ORC group (P = 0.002).22
In contrast, Al-Daghmin et al. investigated the RARC out-
comes and predictors of readmission.23 Of the participating
patients, 25.5% were readmitted within 90 days and the
causes of readmission were mostly infection-related.23 Four
patients (1.4%) required reoperation (two patients for appen-
dicitis and adhesive small bowel obstruction, and two for
ureteroenteric stricture), and six (2.2%) required percutaneous
procedures (three patients for pelvic ﬂuid collections, two for
ureterocutaneous ﬁstula and one for anastomotic leak).23 On
multivariate analysis, body mass index (P = 0.004) and
female sex (P = 0.014) were independent predictors of read-
mission within 90 days.23 Indeed, RARC can be safely car-
ried out with acceptably low risk of EBL, blood transfusion
and LOS. However, we should always keep the risk of post-
operative complications, including readmission or reoperation,
in mind.
Oncological outcomes
In recent years, several authors have described the feasibility
of robotic approaches for BCa patients undergoing RC.8,10,20
Yuh et al. carried out a systematic review and cumulative
analysis of oncological and functional outcomes of RARC.24
At 1, 3 and 5 years, the OS rates were 82–90%, 61–80% and
39–66%, respectively.24 The corresponding DFS rates were
79–96%, 67–76% and 53–74%, respectively.24 However, just
six out of 18 series (33%) reported a mean follow-up period
>36 months.24 In contrast, Raza et al. reported the long-term
oncological outcomes using the IRCC database.11 At a med-
ian follow-up period of 67 months, the OS and DFS rates
Table 1 Pathological outcomes
RARC cohort MIE-RC cohort P
No. patients 29 196
Pathological stage, n (%)
T0 10 (34.5) 42 (21.4) 0.644
T1 11 (37.9) 45 (23)
T2 1 (3.4) 67 (34.2)
T3 6 (20.7) 35 (17.9)
T4 1 (3.4) 7 (3.6)
Lymph node involvement, n (%) 3 (10.3) 16 (8.2) 0.164
Positive surgical margins 0 1 (0.5) >0.999
Median lymph node yield, n (IQR) 15 (12–18) 18 (12–28) 0.747
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Fig. 1 Kaplan–Meier analysis of OS in patients with muscle-invasive BCa
who underwent RARC or MIE-RC. The 5-year OS rate was 80.8% in the RARC
group and 84.6% in the MIE-RC group (P = 0.647).
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were 50% and 67%, respectively.11 Gandaglia et al. reported
the perioperative and oncological outcomes for MIBC
patients who underwent ORC and RARC at two high-volume
centers with a median follow-up period of 54 months.21 After
patient categorization according to the surgical approach
used, no differences were observed in the 5-year OS and
DFS rates between the ORC and RARC groups (58.4 vs
59.2% and 57.1 vs 54.2%, respectively).21 Likewise, Bochner
et al. reported that there were no signiﬁcant differences in
DFS or OS between ORC and RARC.4 However, in that ran-
domized study, it appeared that the patient population was
skewed toward earlier stage disease given the percentage of
patients with organ-conﬁned disease.4 In retrospective RARC
series or prospective series without adequate controls, patient
selection introduces bias, which makes it difﬁcult to directly
compare oncological outcomes between two surgical tech-
niques.4
A long-term analysis of survival of 1100 chemotherapy-
na€ıve ORC patients showed 10-year cancer-speciﬁc survival
and OS rates of 67% and 44%, respectively.3 Moschini et al.
described the recurrence patterns and characteristics related to
survival for 1110 BCa patients who underwent RC at a single
institution after a median follow-up period of 8.4 years.25
Overall, 29.2% of the patients experienced recurrences, and
31.2% died from BCa.25 The 5-year cancer-speciﬁc and over-
all mortality-free rates were 59% and 54%, respectively.25
These reports showed that RARC and ORC provide similar
oncological outcomes, including OS and DFS.4,10,11,21
Although the RC surgical technique and perioperative care
have improved in recent years, the oncological outcomes,
especially OS, for MIBC patients who underwent RC alone
were still low.
Patterns of recurrence after RC
RARC is reported to increase the risk of peritoneal carcino-
matosis, port site recurrences and extrapelvic lymph node
metastases, which might be caused by tumor seeding associ-
ated with pneumoperitoneum, excessive manipulation of the
cystectomy specimens and breach of the specimen bag.25
Table 2 Perioperative outcomes
Study No. patients
Median
age (years)
Median operative
time (min) Median EBL (mL)
Positive surgical
margins (%)
Clavien–Dindo 3–5
complications
Mortality rate (%)Early Late
Koie et al.13 22 67 430 300 0 0 4.5 0
Simone et al.14 45 65 305 210 0 17.8 35.5 0
Parekh et al.26 148 70 428 300 6 22 Not evaluated 3
Lenfant et al.38 74 66 320 400 8.1 20 64.3 0
Tytitzis et al.39 70 59.8 420 500 1.5 31.4 18.3 1.4
Simone et al.40 64 62.5 Not evaluated Not evaluated 0 6.3 Not evaluated 0
Tan et al.41 59 69 330 300 8.5 16.9 30.2 0
Butt et al.42 4 61.8 522 237 0 25 Not evaluated 0
Schwentner et al.43 62 63.6 476.9 385 6.4 25.8 Not evaluated 0
Desai et al.44 132 60 456 430 0.8 15.2 12.9 1.5
Fig. 2 Selection of the appropriate portion of
ileum that reaches the urethra without tension. A
40-cm bowel segment is chosen for the
neobladder. A 14-Fr urethral catheter is inserted
through the urethra to irrigate the ileum.
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According to the Randomized Open versus Robotic Cystec-
tomy trial, which was carried out to investigate whether
RARC was non-inferior to ORC for the treatment of BCa,
the proportion of patients with local recurrences was similar
between the RARC and ORC groups (4% and 3%, respec-
tively; P = 0.54).26 Local recurrence in the cystectomy bed
was also similar in both groups (4% and 1%, respectively;
P = 0.17).26 No port site recurrences were reported.26 In a
recent prospective randomized trial comparing RARC with
ORC, there were no statistically signiﬁcant differences
between the groups, even though the ORC group tended
toward higher overall rates of distant recurrence as their ﬁrst
site of recurrence than the RARC group (27.6% and 16.7%,
respectively; P = 0.077).4 However, the ORC group showed
signiﬁcantly less local/regional recurrence than the RARC
group (10.3% and 16.7%, respectively; P = 0.035).4
MIBC is a systematic disease with distant metastases,
lymph node involvement and local recurrence often caused
by micrometastases at the time of diagnosis. Therefore, early
systemic therapy is important for eradication of the risk of
micrometastases outside the surgical ﬁeld.9
Role of NAC before RC
NAC followed by RC is recommended for MIBC patients
according to the guidelines of the European Urological Asso-
ciation and National Comprehensive Cancer Network.27,28
The most commonly referenced NAC trial is the Southwest-
ern Oncology Group 8710 trial, in which neoadjuvant MVAC
followed by RC was compared with RC alone.29 Although
the difference in 5-year OS was not statistically signiﬁcant
(P = 0.06), the results of that study have been used as evi-
dence of the superiority of NAC over RC alone.29 A meta-
analysis of randomized trials showed that CDDP-based NAC
including MVAC and CMV improves OS by 5% in T2–T4a
BCa patients.29,30 In our previous studies, the oncological
outcomes were signiﬁcantly improved in MIBC patients who
received NAC followed by immediate RC compared with
patients who underwent RC alone.31–33 The 5-year OS rate
was 79.5–98.6% in MIBC patients who received NAC fol-
lowed by immediate RC, and 53.8–66.6% in those who
underwent RC alone (P < 0.001).31–33 The 5-year DFS rate
was 75.5–100% in MIBC patients who received NAC fol-
lowed by immediate RC, and 55.4–69.7% in those who
underwent RC alone (P < 0.001).31–33
In contrast, few studies have investigated the utility and
efﬁcacy of NAC in patients with MIBC who underwent
RARC.9,34 Hinata et al. compared the perioperative and
oncological outcomes after RARC in MIBC patients who
received three cycles of CDDP-based NAC (optimal NAC)
with those who failed to complete three cycles of NAC or
received a decreased dosage of CDDP-based regimen (subop-
timal NAC), or did not receive NAC (no NAC).34 The opti-
mal NAC group had better 1- and 3-year recurrence-free
survival rates (85.4% and 75.2%, respectively) in comparison
with the suboptimal group (55.3% and 33.2%, respectively)
and the no NAC group (55% and 39%; P < 0.01).34 They
also had better OS at 1 and 3 years (95% and 89%, respec-
tively), compared with the suboptimal (64% and 49%, respec-
tively) and the no NAC group (76% and 50%, respectively;
P < 0.01).34 Multivariate analysis showed that recurrence-free
survival in the suboptimal NAC and no NAC groups were
signiﬁcantly lower than in the optimal NAC group
(P = 0.001, P = 0.001, respectively).34 In addition, there
were no signiﬁcant differences in DFS and OS between the
suboptimal NAC and no NAC groups.34 In our previous
study, we evaluated 29 MIBC patients who received NAC
followed by RARC and compared results with those of
patients treated by MIE-RC.9 In the RARC cohort, four
patients (13.8%) showed a complete response, four (13.8%)
Fig. 3 The ileal loop is fixed to the pelvic floor
to facilitate ease of handling and the neobladder-
urethral anastomosis.
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showed a partial response and two (6.9%) showed stable dis-
ease (Table 1). In the MIE-RC cohort, 27 patients (13.8%)
showed a complete response, and 80 (40.8%) showed a par-
tial response. Table 1 lists the histopathological details. By
the end of the follow-up period, 10.3% and 11.7% of the
patients in the RARC and MIE-RC groups, respectively, had
died of BCa.9 The 5-year OS rate was 80.8% in the RARC
group and 84.6% in the MIE-RC group (Fig. 1; P = 0.647).
Combination therapy with NAC and RARC might result in
favorable and acceptable oncological outcomes in patients
with MIBC.
ICUD after RARC
With increasing surgical experience, ICUD is gradually being
adopted, thereby affording potential beneﬁts including
Fig. 4 The detubularized ileal loop is arranged in
an inverted U-shape and the inner opposite
borders are over-sewn with a single-layer
seromuscular running suture.
Fig. 5 After the ureteral anastomosis, the U-flap
is cross-folded to make a pouch.
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decreased ﬂuid loss, reduced EBL, less pain, smaller surgical
incisions, quicker return of bowel function and fewer anasto-
motic strictures.12 The urinary reconstruction probably has
more impact on postoperative morbidity and complications
than RC.35 The rationale for ECUD is the shorter operative
time and the pre-existing need for an extraction site for the
specimens.35 Therefore, most surgeons still consider ECUD a
safer option, and carry out the hybrid approach of RARC and
ECUD.36,37 On review of the literature, we identiﬁed 10 stud-
ies with RARC followed by ICUD (Table 2).13,14,26,38–44 The
IRCC study retrospectively compared the perioperative out-
comes in 935 patients undergoing ICUD (n = 167) and
ECUD (n = 768) followed by RARC.37 Although there were
no statistically signiﬁcant differences in the 90-day complica-
tion rates, the ICUD group tended to have fewer overall com-
plications (P = 0.059), signiﬁcantly fewer gastrointestinal
complications (P < 0.001) and lower transfusion rates
(P = 0.02).37 Lenfant et al. investigated the perioperative out-
comes and complications of ECUD and ICUD in patients
undergoing RARC at ﬁve referral centers in France.38 Over-
all, the operative time, LOS, positive margin rate and number
of lymph nodes removed did not differ signiﬁcantly between
the two cohorts.38 EBL and transfusion rates were signiﬁ-
cantly higher in the ECUD group.38 The early and late surgi-
cal complications did not differ signiﬁcantly between the
ECUD and ICUD groups.38
In our previous study, we compared the oncological and
functional outcomes of 22 MIBC patients who underwent
RARC with U-shaped ICNB or MIE-RC with ECNB.13 Our
surgical technique for RARC has been described in detail pre-
viously.13 Brieﬂy, the ﬁrst step is to identify the most mobile
ileum that reaches the urethra without tension (Fig. 2). A
40-cm bowel segment is chosen for the neobladder. The sec-
ond step is to ﬁx the ileal segment at the pelvic ﬂoor using a
3-0 V-Loc suture (Covidien, Mansﬁeld, MA, USA) (Fig. 3).
The third step is to make the ileourethral anastomosis. After
the anastomosis is complete, the ileal loop is arranged in an
inverted U-shape and the inner opposite borders are over-sewn
with a single-layer seromuscular running suture (Fig. 4). The
fourth step is to make the ileoureteral anastomosis. Two small
enterotomies are created in the U-ﬂap and the ureters are intro-
duced into the future neobladder. A 4-0 braided polyglactin
suture is used to make an anastomosis with interrupted sutures.
After ureteral anastomosis, the U-ﬂap is cross-folded to make
a pouch (Fig. 5). The operative time in the ICNB group was
signiﬁcantly longer than in the ECNB group.13 The median
EBL was less and the transfusion rate was signiﬁcantly lower
in the ICNB group than in the ECNB group (P < 0.001).13 In
contrast, the rate of postoperative ileus in the ICNB group was
relative higher than in the ECNB group. Several steps have
been shown to have a causative role in postoperative ileus.
However, there were no statistically signiﬁcant differences in
the major complications between the two groups (Table 3).13
In addition, the rate of postoperative ileus was not high in our
series.13 Indeed, totally ICUD technique increased the com-
plexity of the procedure. However, the surgical outcomes and
complication rates after RARC with ICUD might improve
with more experience if the ICUD surgical techniques are
standardized.
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Editorial Comment
Editorial Comment to Utility of robot-assisted radical cystectomy with intracorporeal
urinary diversion for muscle-invasive bladder cancer
Koie et al. reviewed the usefulness of robot-assisted radical
cystectomy (RARC) with intracorporeal urinary diversion
(ICUD) for muscle-invasive bladder cancer.1 The authors
described the oncological outcome, morbidities, pattern of
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